NBIX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of --. Neurocrine Biosciences's return on equity of 13.72% beat Armata Pharmaceuticals's return on equity of --.

Neurocrine Biosciences has a consensus price target of $162.73, signalling upside risk potential of 85.89%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 527.8%. Given that Armata Pharmaceuticals has higher upside potential than Neurocrine Biosciences, analysts believe Armata Pharmaceuticals is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.595%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Neurocrine Biosciences's net income of $103.1M is higher than Armata Pharmaceuticals's net income of $2.6M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 26.61x while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 3.85x versus 404.15x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

bluebird bio has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of -573.01%. Neurocrine Biosciences's return on equity of 13.72% beat bluebird bio's return on equity of -245.94%.

Neurocrine Biosciences has a consensus price target of $162.73, signalling upside risk potential of 85.89%. On the other hand bluebird bio has an analysts' consensus of $6.50 which suggests that it could grow by 34.86%. Given that Neurocrine Biosciences has higher upside potential than bluebird bio, analysts believe Neurocrine Biosciences is more attractive than bluebird bio.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison bluebird bio has a beta of 0.431, suggesting its less volatile than the S&P 500 by 56.869%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. bluebird bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. bluebird bio pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than bluebird bio quarterly revenues of $10.6M. Neurocrine Biosciences's net income of $103.1M is higher than bluebird bio's net income of -$60.8M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 26.61x while bluebird bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 3.85x versus 0.56x for bluebird bio. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of --. Neurocrine Biosciences's return on equity of 13.72% beat Perspective Therapeutics's return on equity of --.

Neurocrine Biosciences has a consensus price target of $162.73, signalling upside risk potential of 85.89%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 741.69%. Given that Perspective Therapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Perspective Therapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Neurocrine Biosciences's net income of $103.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 26.61x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 3.85x versus 11.07x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of 35.65%. Neurocrine Biosciences's return on equity of 13.72% beat Protalix BioTherapeutics's return on equity of 8.75%.

Neurocrine Biosciences has a consensus price target of $162.73, signalling upside risk potential of 85.89%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 535.97%. Given that Protalix BioTherapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Protalix BioTherapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Protalix BioTherapeutics quarterly revenues of $18.2M. Neurocrine Biosciences's net income of $103.1M is higher than Protalix BioTherapeutics's net income of $6.5M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 26.61x while Protalix BioTherapeutics's PE ratio is 76.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 3.85x versus 3.54x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.